<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Diabetes Investig</journal-id><journal-id journal-id-type="iso-abbrev">J Diabetes Investig</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)2040-1124</journal-id><journal-id journal-id-type="publisher-id">JDI</journal-id><journal-title-group><journal-title>Journal of Diabetes Investigation</journal-title></journal-title-group><issn pub-type="ppub">2040-1116</issn><issn pub-type="epub">2040-1124</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29750107</article-id><article-id pub-id-type="pmc">5934252</article-id><article-id pub-id-type="doi">10.1111/jdi.12726</article-id><article-id pub-id-type="publisher-id">JDI12726</article-id><article-categories><subj-group subj-group-type="overline"><subject>Letter to the Editor</subject></subj-group><subj-group subj-group-type="heading"><subject>Letters to the Editor</subject></subj-group></article-categories><title-group><article-title>Changes in heart rate in patients with type&#x000a0;2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo&#x02010;controlled, double&#x02010;blind clinical trials</article-title><alt-title alt-title-type="left-running-head">Sano <italic>et al</italic>.</alt-title></title-group><contrib-group><contrib id="jdi12726-cr-0001" contrib-type="author"><name><surname>Sano</surname><given-names>Motoaki</given-names></name><xref ref-type="aff" rid="jdi12726-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jdi12726-cr-0002" contrib-type="author"><name><surname>Chen</surname><given-names>Shi</given-names></name><xref ref-type="aff" rid="jdi12726-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jdi12726-cr-0003" contrib-type="author"><name><surname>Imazeki</surname><given-names>Hisae</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7207-0014</contrib-id><xref ref-type="aff" rid="jdi12726-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jdi12726-cr-0004" contrib-type="author" corresp="yes"><name><surname>Ochiai</surname><given-names>Hidekazu</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9370-540X</contrib-id><address><email>h-ochiai@so.taisho.co.jp</email></address><xref ref-type="aff" rid="jdi12726-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jdi12726-cr-0005" contrib-type="author"><name><surname>Seino</surname><given-names>Yutaka</given-names></name><xref ref-type="aff" rid="jdi12726-aff-0003">
<sup>3</sup>
</xref></contrib></contrib-group><aff id="jdi12726-aff-0001">
<label><sup>1</sup></label>
<institution>Keio University of Medicine</institution>
<named-content content-type="city">Tokyo</named-content>
<country>Japan</country>
</aff><aff id="jdi12726-aff-0002">
<label><sup>2</sup></label>
<institution>Taisho Pharmaceutical Co., Ltd.</institution>
<named-content content-type="city">Tokyo</named-content>
<country>Japan</country>
</aff><aff id="jdi12726-aff-0003">
<label><sup>3</sup></label>
<institution>Kansai Electric Power Hospital</institution>
<named-content content-type="city">Osaka</named-content>
<country country="JP">Japan</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>
Corresponding author. Hidekazu Ochiai<break/>
Tel.: +81&#x02010;3&#x02010;3985&#x02010;1111<break/>
Fax: +81&#x02010;3&#x02010;3985&#x02010;0650<break/>
E&#x02010;mail address: <email>h-ochiai@so.taisho.co.jp</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>5</month><year>2018</year></pub-date><pub-date pub-type="ppub"><month>5</month><year>2018</year></pub-date><volume>9</volume><issue>3</issue><issue-id pub-id-type="doi">10.1111/jdi.2018.9.issue-3</issue-id><fpage>638</fpage><lpage>641</lpage><history><date date-type="received"><day>26</day><month>4</month><year>2017</year></date><date date-type="rev-recd"><day>28</day><month>7</month><year>2017</year></date><date date-type="accepted"><day>06</day><month>8</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2018 Asian Association for the Study of Diabetes and John Wiley & Sons Australia, Ltd <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2018 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley &#x00026; Sons Australia, Ltd</copyright-statement><license license-type="creativeCommonsBy-nc-nd"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non&#x02010;commercial and no modifications or adaptations are made.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JDI-9-638.pdf"/><abstract abstract-type="toc" id="jdi12726-abs-0001"><p>We evaluated the changes in heart rate on the treatment with SGLT2 inhibitor, luseogliflozin, in Japanese patients with type 2 diabetes mellitus (T2DM). It is suggested that luseogliflozin can effectively decrease in heart rate in patients with higher baseline.<boxed-text position="anchor" content-type="graphic" id="jdi12726-blkfxd-0001" orientation="portrait"><graphic xlink:href="JDI-9-638-g001.jpg" position="anchor" id="nlm-graphic-1" orientation="portrait"/></boxed-text>
</p></abstract><funding-group><award-group><funding-source>Nippon Boehringer Ingelheim Co., Ltd</funding-source></award-group><award-group><funding-source>Eli Lilly and Company</funding-source></award-group><award-group><funding-source>Taisho Toyama Pharmaceutical Co., Ltd</funding-source></award-group><award-group><funding-source>MSD K.K.</funding-source></award-group><award-group><funding-source>Ono Pharmaceutical Co., Ltd.</funding-source></award-group><award-group><funding-source>Novo Nordisk Pharma Ltd.</funding-source></award-group><award-group><funding-source>ARKRAY, Inc</funding-source></award-group><award-group><funding-source>Taisho Pharmaceutical Co., Ltd</funding-source></award-group></funding-group><counts><fig-count count="0"/><table-count count="1"/><page-count count="4"/><word-count count="2838"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jdi12726</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>May 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.3.7.2 mode:remove_FC converted:03.05.2018</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>In patients with type&#x000a0;2 diabetes mellitus, higher heart rate (HR) is associated with an increased risk of death and cardiovascular complications<xref rid="jdi12726-bib-0001" ref-type="ref">1</xref>. Sodium&#x02013;glucose cotransporter&#x000a0;2 inhibitors were approved as novel antihyperglycemic agents, and are known to decrease blood glucose levels without affecting HR. However, to the best of our knowledge, no detailed analysis has been undertaken in patients stratified by baseline HR. In the present study, we evaluated the changes in HR after treatment with the sodium&#x02013;glucose cotransporter&#x000a0;2 inhibitor, luseogliflozin, in Japanese patients with type&#x000a0;2 diabetes mellitus.</p><p>Three placebo&#x02010;controlled, double&#x02010;blind studies of luseogliflozin, including two dose&#x02010;finding phase&#x000a0;2 studies and a phase&#x000a0;3 randomized study, were merged in this pooled analysis. These studies are registered at the Japan Pharmaceutical Information Center (identifier: JapicCTI&#x02010;090908, JapicCTI&#x02010;101191 and JapicCTI&#x02010;111661)<xref rid="jdi12726-bib-0002" ref-type="ref">2</xref>, <xref rid="jdi12726-bib-0003" ref-type="ref">3</xref>, <xref rid="jdi12726-bib-0004" ref-type="ref">4</xref>. The major inclusion criteria were as follows: Japanese patients with type&#x000a0;2 diabetes mellitus receiving diet and exercise therapy alone, age &#x02265;20&#x000a0;years and with glycated hemoglobin levels &#x02265;6.9% to &#x02264;10.5%. The changes in HR from baseline to 12&#x000a0;weeks after treatment with luseogliflozin were assessed by using a paired <italic>t</italic>&#x02010;test and an analysis of covariance with baseline as a covariate at a two&#x02010;sided &#x003b1; level of 0.05. Other clinical parameters were similarly measured using a paired <italic>t</italic>&#x02010;test. Missing data were not imputed, and all analyses were carried out using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA).</p><p>Of 501 patients enrolled in the three studies, 489 were included in this pooled analysis. The patients were divided into three groups as follows: placebo, <italic>n</italic>&#x000a0;=&#x000a0;183; luseogliflozin 2.5&#x000a0;mg, <italic>n</italic>&#x000a0;=&#x000a0;194; luseogliflozin 5.0&#x000a0;mg, <italic>n</italic>&#x000a0;=&#x000a0;112. The mean&#x000a0;&#x000b1;&#x000a0;standard deviation age was 58.3&#x000a0;&#x000b1;&#x000a0;10.0, 58.2&#x000a0;&#x000b1;&#x000a0;9.6 and 56.8&#x000a0;&#x000b1;&#x000a0;10.3&#x000a0;years; glycated hemoglobin levels were 7.98&#x000a0;&#x000b1;&#x000a0;0.74%, 8.09&#x000a0;&#x000b1;&#x000a0;0.86% and 8.02&#x000a0;&#x000b1;&#x000a0;0.87%; and number (percentage) of male patients was 132 (72.1), 131 (67.5) and 83 (74.1), respectively.</p><p>Table&#x000a0;<xref rid="jdi12726-tbl-0001" ref-type="table-wrap">1</xref> shows the changes in clinical parameters from baseline to 12&#x000a0;weeks when the patients were stratified by baseline HR. Treatment with both luseogliflozin 2.5&#x000a0;mg and 5.0&#x000a0;mg showed significant reductions in HR from baseline in patients with HR &#x0003e;70&#x000a0;b.p.m. Detailed stratification of patients with HR &#x0003e;70&#x000a0;b.p.m. showed that luseogliflozin 2.5&#x000a0;mg significantly decreased the HR in all subgroups compared with the baseline HR, whereas luseogliflozin 5.0&#x000a0;mg significantly decreased the HR only in patients with baseline HR &#x0003e;80&#x000a0;b.p.m. In addition, the decrease with 2.5&#x000a0;mg, but not 5.0&#x000a0;mg, luseogliflozin was also significant compared with the placebo (<italic>P</italic>&#x000a0;=&#x000a0;0.016). Although the reason for this result is unknown, it is to be noted that high&#x02010;density lipoprotein cholesterol and blood urea nitrogen levels were significantly increased from baseline in patients with lower baseline HR (&#x0003c;70&#x000a0;b.p.m.) in the luseogliflozin 2.5&#x000a0;mg group. Additionally, there was no correlation between the change in each parameter from baseline in Table&#x000a0;<xref rid="jdi12726-tbl-0001" ref-type="table-wrap">1</xref> and the change in HR from baseline.</p><table-wrap id="jdi12726-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Changes in clinical parameters from baseline to week 12 for all heart rate groups receiving luseogliflozin</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" rowspan="2" colspan="2" valign="top">Variable (heart rate at baseline)</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">Placebo</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">2.5 mg luseogliflozin</th><th align="left" colspan="2" style="border-bottom:solid 1px #000000" valign="top" rowspan="1">5.0 mg luseogliflozin</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">&#x0003c;70 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;70 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x0003c;70 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;70 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x0003c;70 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;70 b.p.m.</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">FPG (mg/dL)</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">130</td><td align="left" rowspan="1" colspan="1">53</td><td align="left" rowspan="1" colspan="1">138</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">45</td></tr><tr><td align="left" rowspan="1" colspan="1">Changes at week 12</td><td align="left" rowspan="1" colspan="1">0.4&#x000a0;&#x000b1;&#x000a0;1.8</td><td align="left" rowspan="1" colspan="1">0.8&#x000a0;&#x000b1;&#x000a0;3.4</td><td align="left" rowspan="1" colspan="1">&#x02212;19.1&#x000a0;&#x000b1;&#x000a0;2.0<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;32.1&#x000a0;&#x000b1;&#x000a0;3.4<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;24.2&#x000a0;&#x000b1;&#x000a0;3.1<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;22.6&#x000a0;&#x000b1;&#x000a0;5.1<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">(154.8&#x000a0;&#x000b1;&#x000a0;2.3)</td><td align="left" rowspan="1" colspan="1">(160.4&#x000a0;&#x000b1;&#x000a0;4.5)</td><td align="left" rowspan="1" colspan="1">(152.9&#x000a0;&#x000b1;&#x000a0;2.1)</td><td align="left" rowspan="1" colspan="1">(171.2&#x000a0;&#x000b1;&#x000a0;4.5)</td><td align="left" rowspan="1" colspan="1">(155.4&#x000a0;&#x000b1;&#x000a0;3.7)</td><td align="left" rowspan="1" colspan="1">(156.0&#x000a0;&#x000b1;&#x000a0;4.6)</td></tr><tr><td align="left" rowspan="3" colspan="1">HbA1c (%)</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">130</td><td align="left" rowspan="1" colspan="1">53</td><td align="left" rowspan="1" colspan="1">138</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">46</td></tr><tr><td align="left" rowspan="1" colspan="1">Changes at week 12</td><td align="left" rowspan="1" colspan="1">0.09&#x000a0;&#x000b1;&#x000a0;0.05</td><td align="left" rowspan="1" colspan="1">0.15&#x000a0;&#x000b1;&#x000a0;0.08</td><td align="left" rowspan="1" colspan="1">&#x02212;0.49&#x000a0;&#x000b1;&#x000a0;0.05<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;0.68&#x000a0;&#x000b1;&#x000a0;0.10<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;0.56&#x000a0;&#x000b1;&#x000a0;0.07<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;0.70&#x000a0;&#x000b1;&#x000a0;0.08<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">(7.97&#x000a0;&#x000b1;&#x000a0;0.06)</td><td align="left" rowspan="1" colspan="1">(8.01&#x000a0;&#x000b1;&#x000a0;0.12)</td><td align="left" rowspan="1" colspan="1">(7.95&#x000a0;&#x000b1;&#x000a0;0.06)</td><td align="left" rowspan="1" colspan="1">(8.44&#x000a0;&#x000b1;&#x000a0;0.14)</td><td align="left" rowspan="1" colspan="1">(7.97&#x000a0;&#x000b1;&#x000a0;0.11)</td><td align="left" rowspan="1" colspan="1">(8.10&#x000a0;&#x000b1;&#x000a0;0.13)</td></tr><tr><td align="left" rowspan="3" colspan="1">Body weight (kg)</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">130</td><td align="left" rowspan="1" colspan="1">53</td><td align="left" rowspan="1" colspan="1">138</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">46</td></tr><tr><td align="left" rowspan="1" colspan="1">Changes at week 12</td><td align="left" rowspan="1" colspan="1">&#x02212;0.22&#x000a0;&#x000b1;&#x000a0;0.11<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;0.32&#x000a0;&#x000b1;&#x000a0;0.21</td><td align="left" rowspan="1" colspan="1">&#x02212;1.74&#x000a0;&#x000b1;&#x000a0;0.11<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;1.95&#x000a0;&#x000b1;&#x000a0;0.22<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;2.04&#x000a0;&#x000b1;&#x000a0;0.17<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;2.06&#x000a0;&#x000b1;&#x000a0;0.23<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">(67.15&#x000a0;&#x000b1;&#x000a0;1.09)</td><td align="left" rowspan="1" colspan="1">(68.38&#x000a0;&#x000b1;&#x000a0;1.78)</td><td align="left" rowspan="1" colspan="1">(66.34&#x000a0;&#x000b1;&#x000a0;0.93)</td><td align="left" rowspan="1" colspan="1">(70.96&#x000a0;&#x000b1;&#x000a0;2.14)</td><td align="left" rowspan="1" colspan="1">(68.81&#x000a0;&#x000b1;&#x000a0;1.70)</td><td align="left" rowspan="1" colspan="1">(70.00&#x000a0;&#x000b1;&#x000a0;1.96)</td></tr><tr><td align="left" rowspan="3" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">130</td><td align="left" rowspan="1" colspan="1">53</td><td align="left" rowspan="1" colspan="1">138</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">46</td></tr><tr><td align="left" rowspan="1" colspan="1">Changes at week 12</td><td align="left" rowspan="1" colspan="1">&#x02212;0.08&#x000a0;&#x000b1;&#x000a0;0.04</td><td align="left" rowspan="1" colspan="1">&#x02212;0.12&#x000a0;&#x000b1;&#x000a0;0.08</td><td align="left" rowspan="1" colspan="1">&#x02212;0.66&#x000a0;&#x000b1;&#x000a0;0.04<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;0.71&#x000a0;&#x000b1;&#x000a0;0.07<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;0.77&#x000a0;&#x000b1;&#x000a0;0.06<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;0.72&#x000a0;&#x000b1;&#x000a0;0.08<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">(25.47&#x000a0;&#x000b1;&#x000a0;0.35)</td><td align="left" rowspan="1" colspan="1">(24.90&#x000a0;&#x000b1;&#x000a0;0.56)</td><td align="left" rowspan="1" colspan="1">(24.74&#x000a0;&#x000b1;&#x000a0;0.30)</td><td align="left" rowspan="1" colspan="1">(26.50&#x000a0;&#x000b1;&#x000a0;0.74)</td><td align="left" rowspan="1" colspan="1">(25.69&#x000a0;&#x000b1;&#x000a0;0.50)</td><td align="left" rowspan="1" colspan="1">(24.89&#x000a0;&#x000b1;&#x000a0;0.50)</td></tr><tr><td align="left" rowspan="3" colspan="1">Uric acid (mg/dL)</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">131</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">137</td><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">46</td></tr><tr><td align="left" rowspan="1" colspan="1">Changes at week 12</td><td align="left" rowspan="1" colspan="1">&#x02212;0.09&#x000a0;&#x000b1;&#x000a0;0.05</td><td align="left" rowspan="1" colspan="1">&#x02212;0.10&#x000a0;&#x000b1;&#x000a0;0.07</td><td align="left" rowspan="1" colspan="1">&#x02212;0.62&#x000a0;&#x000b1;&#x000a0;0.06<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;0.57&#x000a0;&#x000b1;&#x000a0;0.12<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;0.56&#x000a0;&#x000b1;&#x000a0;0.09<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;0.42&#x000a0;&#x000b1;&#x000a0;0.13<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">(5.12&#x000a0;&#x000b1;&#x000a0;0.10)</td><td align="left" rowspan="1" colspan="1">(5.22&#x000a0;&#x000b1;&#x000a0;0.17)</td><td align="left" rowspan="1" colspan="1">(5.16&#x000a0;&#x000b1;&#x000a0;0.10)</td><td align="left" rowspan="1" colspan="1">(5.10&#x000a0;&#x000b1;&#x000a0;0.20)</td><td align="left" rowspan="1" colspan="1">(4.90&#x000a0;&#x000b1;&#x000a0;0.14)</td><td align="left" rowspan="1" colspan="1">(5.25&#x000a0;&#x000b1;&#x000a0;0.20)</td></tr><tr><td align="left" rowspan="3" colspan="1">Triglycerides (mg/dL)</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">131</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">137</td><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">46</td></tr><tr><td align="left" rowspan="1" colspan="1">Changes at week 12</td><td align="left" rowspan="1" colspan="1">&#x02212;8.3&#x000a0;&#x000b1;&#x000a0;7.7</td><td align="left" rowspan="1" colspan="1">9.9&#x000a0;&#x000b1;&#x000a0;12.1</td><td align="left" rowspan="1" colspan="1">&#x02212;26.8&#x000a0;&#x000b1;&#x000a0;6.2<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;35.9&#x000a0;&#x000b1;&#x000a0;12.5<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;16.1&#x000a0;&#x000b1;&#x000a0;5.5<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;40.2&#x000a0;&#x000b1;&#x000a0;17.6<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">(154.0&#x000a0;&#x000b1;&#x000a0;12.5)</td><td align="left" rowspan="1" colspan="1">(165.6&#x000a0;&#x000b1;&#x000a0;19.7)</td><td align="left" rowspan="1" colspan="1">(147.6&#x000a0;&#x000b1;&#x000a0;7.9)</td><td align="left" rowspan="1" colspan="1">(167.8&#x000a0;&#x000b1;&#x000a0;14.3)</td><td align="left" rowspan="1" colspan="1">(125.7&#x000a0;&#x000b1;&#x000a0;7.9)</td><td align="left" rowspan="1" colspan="1">(185.3&#x000a0;&#x000b1;&#x000a0;25.9)</td></tr><tr><td align="left" rowspan="3" colspan="1">HDL&#x02010;C (mg/dL)</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">97</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">97</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">Changes at week 12</td><td align="left" rowspan="1" colspan="1">0.8&#x000a0;&#x000b1;&#x000a0;0.8</td><td align="left" rowspan="1" colspan="1">&#x02212;0.6&#x000a0;&#x000b1;&#x000a0;1.4</td><td align="left" rowspan="1" colspan="1">4.0&#x000a0;&#x000b1;&#x000a0;0.8<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">1.8&#x000a0;&#x000b1;&#x000a0;1.1</td><td align="left" rowspan="1" colspan="1">3.7&#x000a0;&#x000b1;&#x000a0;1.1<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">6.6&#x000a0;&#x000b1;&#x000a0;1.5<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">(57.5&#x000a0;&#x000b1;&#x000a0;1.5)</td><td align="left" rowspan="1" colspan="1">(59.6&#x000a0;&#x000b1;&#x000a0;3.0)</td><td align="left" rowspan="1" colspan="1">(57.9&#x000a0;&#x000b1;&#x000a0;1.6)</td><td align="left" rowspan="1" colspan="1">(51.8&#x000a0;&#x000b1;&#x000a0;2.1)</td><td align="left" rowspan="1" colspan="1">(54.0&#x000a0;&#x000b1;&#x000a0;2.3)</td><td align="left" rowspan="1" colspan="1">(53.0&#x000a0;&#x000b1;&#x000a0;3.1)</td></tr><tr><td align="left" rowspan="3" colspan="1">LDL&#x02010;C (mg/dL)</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">97</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">97</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">18</td></tr><tr><td align="left" rowspan="1" colspan="1">Changes at week 12</td><td align="left" rowspan="1" colspan="1">0.8&#x000a0;&#x000b1;&#x000a0;2.1</td><td align="left" rowspan="1" colspan="1">&#x02212;3.3&#x000a0;&#x000b1;&#x000a0;3.2</td><td align="left" rowspan="1" colspan="1">0.4&#x000a0;&#x000b1;&#x000a0;2.1</td><td align="left" rowspan="1" colspan="1">4.6&#x000a0;&#x000b1;&#x000a0;3.4</td><td align="left" rowspan="1" colspan="1">6.2&#x000a0;&#x000b1;&#x000a0;3.3</td><td align="left" rowspan="1" colspan="1">10.2&#x000a0;&#x000b1;&#x000a0;5.3</td></tr><tr><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">(124.5&#x000a0;&#x000b1;&#x000a0;3.3)</td><td align="left" rowspan="1" colspan="1">(119.1&#x000a0;&#x000b1;&#x000a0;5.7)</td><td align="left" rowspan="1" colspan="1">(128.3&#x000a0;&#x000b1;&#x000a0;2.8)</td><td align="left" rowspan="1" colspan="1">(133.5&#x000a0;&#x000b1;&#x000a0;4.7)</td><td align="left" rowspan="1" colspan="1">(117.8&#x000a0;&#x000b1;&#x000a0;3.9)</td><td align="left" rowspan="1" colspan="1">(108.4&#x000a0;&#x000b1;&#x000a0;7.5)</td></tr><tr><td align="left" rowspan="3" colspan="1">ALT (IU/L/37&#x000b0;C)</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">131</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">137</td><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">46</td></tr><tr><td align="left" rowspan="1" colspan="1">Changes at week 12</td><td align="left" rowspan="1" colspan="1">&#x02212;1.7&#x000a0;&#x000b1;&#x000a0;0.8<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;1.5&#x000a0;&#x000b1;&#x000a0;0.9</td><td align="left" rowspan="1" colspan="1">&#x02212;5.0&#x000a0;&#x000b1;&#x000a0;0.9<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;8.4&#x000a0;&#x000b1;&#x000a0;1.5<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;4.5&#x000a0;&#x000b1;&#x000a0;1.4<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;2.6&#x000a0;&#x000b1;&#x000a0;1.0<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">(30.9&#x000a0;&#x000b1;&#x000a0;1.5)</td><td align="left" rowspan="1" colspan="1">(26.5&#x000a0;&#x000b1;&#x000a0;2.0)</td><td align="left" rowspan="1" colspan="1">(27.9&#x000a0;&#x000b1;&#x000a0;1.2)</td><td align="left" rowspan="1" colspan="1">(33.0&#x000a0;&#x000b1;&#x000a0;2.7)</td><td align="left" rowspan="1" colspan="1">(26.0&#x000a0;&#x000b1;&#x000a0;2.0)</td><td align="left" rowspan="1" colspan="1">(26.5&#x000a0;&#x000b1;&#x000a0;2.4)</td></tr><tr><td align="left" rowspan="3" colspan="1">AST (IU/L/37&#x000b0;C)</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">131</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">137</td><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">46</td></tr><tr><td align="left" rowspan="1" colspan="1">Changes at week 12</td><td align="left" rowspan="1" colspan="1">&#x02212;0.5&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="left" rowspan="1" colspan="1">&#x02212;0.9&#x000a0;&#x000b1;&#x000a0;0.6</td><td align="left" rowspan="1" colspan="1">&#x02212;2.6&#x000a0;&#x000b1;&#x000a0;0.6<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;4.3&#x000a0;&#x000b1;&#x000a0;1.0<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;1.5&#x000a0;&#x000b1;&#x000a0;1.1</td><td align="left" rowspan="1" colspan="1">&#x02212;0.1&#x000a0;&#x000b1;&#x000a0;0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">(27.1&#x000a0;&#x000b1;&#x000a0;0.9)</td><td align="left" rowspan="1" colspan="1">(25.2&#x000a0;&#x000b1;&#x000a0;1.1)</td><td align="left" rowspan="1" colspan="1">(26.3&#x000a0;&#x000b1;&#x000a0;0.9)</td><td align="left" rowspan="1" colspan="1">(27.6&#x000a0;&#x000b1;&#x000a0;1.6)</td><td align="left" rowspan="1" colspan="1">(23.9&#x000a0;&#x000b1;&#x000a0;1.3)</td><td align="left" rowspan="1" colspan="1">(24.1&#x000a0;&#x000b1;&#x000a0;1.3)</td></tr><tr><td align="left" rowspan="3" colspan="1">Hemoglobin (g/dL)</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">131</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">137</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">46</td></tr><tr><td align="left" rowspan="1" colspan="1">Changes at week 12</td><td align="left" rowspan="1" colspan="1">0.21&#x000a0;&#x000b1;&#x000a0;0.05<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">0.15&#x000a0;&#x000b1;&#x000a0;0.08</td><td align="left" rowspan="1" colspan="1">0.71&#x000a0;&#x000b1;&#x000a0;0.06<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">0.63&#x000a0;&#x000b1;&#x000a0;0.09<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">0.88&#x000a0;&#x000b1;&#x000a0;0.08<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">1.00&#x000a0;&#x000b1;&#x000a0;0.11<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">(14.39&#x000a0;&#x000b1;&#x000a0;0.10)</td><td align="left" rowspan="1" colspan="1">(14.67&#x000a0;&#x000b1;&#x000a0;0.18)</td><td align="left" rowspan="1" colspan="1">(14.48&#x000a0;&#x000b1;&#x000a0;0.10)</td><td align="left" rowspan="1" colspan="1">(14.36&#x000a0;&#x000b1;&#x000a0;0.18)</td><td align="left" rowspan="1" colspan="1">(14.21&#x000a0;&#x000b1;&#x000a0;0.15)</td><td align="left" rowspan="1" colspan="1">(14.67&#x000a0;&#x000b1;&#x000a0;0.15)</td></tr><tr><td align="left" rowspan="3" colspan="1">Hematocrit (%)</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">131</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">137</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">46</td></tr><tr><td align="left" rowspan="1" colspan="1">Changes at week 12</td><td align="left" rowspan="1" colspan="1">0.64&#x000a0;&#x000b1;&#x000a0;0.16<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">0.49&#x000a0;&#x000b1;&#x000a0;0.24<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">2.34&#x000a0;&#x000b1;&#x000a0;0.18<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">2.05&#x000a0;&#x000b1;&#x000a0;0.29<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">2.76&#x000a0;&#x000b1;&#x000a0;0.26<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">2.79&#x000a0;&#x000b1;&#x000a0;0.34<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">(42.24&#x000a0;&#x000b1;&#x000a0;0.30)</td><td align="left" rowspan="1" colspan="1">(42.99&#x000a0;&#x000b1;&#x000a0;0.49)</td><td align="left" rowspan="1" colspan="1">(42.57&#x000a0;&#x000b1;&#x000a0;0.30)</td><td align="left" rowspan="1" colspan="1">(42.16&#x000a0;&#x000b1;&#x000a0;0.49)</td><td align="left" rowspan="1" colspan="1">(41.99&#x000a0;&#x000b1;&#x000a0;0.44)</td><td align="left" rowspan="1" colspan="1">(43.24&#x000a0;&#x000b1;&#x000a0;0.45)</td></tr><tr><td align="left" rowspan="3" colspan="1">BUN (mg/dL)</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">131</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">137</td><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">46</td></tr><tr><td align="left" rowspan="1" colspan="1">Changes at week 12</td><td align="left" rowspan="1" colspan="1">0.0&#x000a0;&#x000b1;&#x000a0;0.2</td><td align="left" rowspan="1" colspan="1">&#x02212;0.3&#x000a0;&#x000b1;&#x000a0;0.3</td><td align="left" rowspan="1" colspan="1">1.1&#x000a0;&#x000b1;&#x000a0;0.3<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">0.7&#x000a0;&#x000b1;&#x000a0;0.4</td><td align="left" rowspan="1" colspan="1">1.5&#x000a0;&#x000b1;&#x000a0;0.3<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">1.4&#x000a0;&#x000b1;&#x000a0;0.5<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">(14.3&#x000a0;&#x000b1;&#x000a0;0.3)</td><td align="left" rowspan="1" colspan="1">(13.3&#x000a0;&#x000b1;&#x000a0;0.4)</td><td align="left" rowspan="1" colspan="1">(14.7&#x000a0;&#x000b1;&#x000a0;0.3)</td><td align="left" rowspan="1" colspan="1">(13.7&#x000a0;&#x000b1;&#x000a0;0.5)</td><td align="left" rowspan="1" colspan="1">(13.7&#x000a0;&#x000b1;&#x000a0;0.4)</td><td align="left" rowspan="1" colspan="1">(13.9&#x000a0;&#x000b1;&#x000a0;0.4)</td></tr><tr><td align="left" rowspan="3" colspan="1">Creatinine (mg/dL)</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">131</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">137</td><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">46</td></tr><tr><td align="left" rowspan="1" colspan="1">Changes at week 12</td><td align="left" rowspan="1" colspan="1">0.000&#x000a0;&#x000b1;&#x000a0;0.005</td><td align="left" rowspan="1" colspan="1">&#x02212;0.004&#x000a0;&#x000b1;&#x000a0;0.006</td><td align="left" rowspan="1" colspan="1">0.002&#x000a0;&#x000b1;&#x000a0;0.005</td><td align="left" rowspan="1" colspan="1">0.001&#x000a0;&#x000b1;&#x000a0;0.008</td><td align="left" rowspan="1" colspan="1">0.009&#x000a0;&#x000b1;&#x000a0;0.007</td><td align="left" rowspan="1" colspan="1">0.018&#x000a0;&#x000b1;&#x000a0;0.010</td></tr><tr><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">(0.692&#x000a0;&#x000b1;&#x000a0;0.013)</td><td align="left" rowspan="1" colspan="1">(0.669&#x000a0;&#x000b1;&#x000a0;0.017)</td><td align="left" rowspan="1" colspan="1">(0.717&#x000a0;&#x000b1;&#x000a0;0.013)</td><td align="left" rowspan="1" colspan="1">(0.652&#x000a0;&#x000b1;&#x000a0;0.020)</td><td align="left" rowspan="1" colspan="1">(0.698&#x000a0;&#x000b1;&#x000a0;0.019)</td><td align="left" rowspan="1" colspan="1">(0.729&#x000a0;&#x000b1;&#x000a0;0.018)</td></tr><tr><td align="left" rowspan="3" colspan="1">SBP (mmHg)</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">131</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">137</td><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">46</td></tr><tr><td align="left" rowspan="1" colspan="1">Changes at week 12</td><td align="left" rowspan="1" colspan="1">0.7&#x000a0;&#x000b1;&#x000a0;1.0</td><td align="left" rowspan="1" colspan="1">&#x02212;1.3&#x000a0;&#x000b1;&#x000a0;1.4</td><td align="left" rowspan="1" colspan="1">&#x02212;6.1&#x000a0;&#x000b1;&#x000a0;1.1<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;6.8&#x000a0;&#x000b1;&#x000a0;1.4<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;4.2&#x000a0;&#x000b1;&#x000a0;1.5<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;5.3&#x000a0;&#x000b1;&#x000a0;2.0<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">(127.2&#x000a0;&#x000b1;&#x000a0;1.1)</td><td align="left" rowspan="1" colspan="1">(126.6&#x000a0;&#x000b1;&#x000a0;2.3)</td><td align="left" rowspan="1" colspan="1">(125.8&#x000a0;&#x000b1;&#x000a0;1.2)</td><td align="left" rowspan="1" colspan="1">(128.0&#x000a0;&#x000b1;&#x000a0;1.7)</td><td align="left" rowspan="1" colspan="1">(127.4&#x000a0;&#x000b1;&#x000a0;1.8)</td><td align="left" rowspan="1" colspan="1">(129.9&#x000a0;&#x000b1;&#x000a0;2.1)</td></tr><tr><td align="left" rowspan="3" colspan="1">DBP (mmHg)</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">131</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">137</td><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">46</td></tr><tr><td align="left" rowspan="1" colspan="1">Changes at week 12</td><td align="left" rowspan="1" colspan="1">1.3&#x000a0;&#x000b1;&#x000a0;0.7</td><td align="left" rowspan="1" colspan="1">&#x02212;0.9&#x000a0;&#x000b1;&#x000a0;1.1</td><td align="left" rowspan="1" colspan="1">&#x02212;2.0&#x000a0;&#x000b1;&#x000a0;0.7<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;4.7&#x000a0;&#x000b1;&#x000a0;1.0<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;2.5&#x000a0;&#x000b1;&#x000a0;0.9<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;1.9&#x000a0;&#x000b1;&#x000a0;1.2</td></tr><tr><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">(75.1&#x000a0;&#x000b1;&#x000a0;0.8)</td><td align="left" rowspan="1" colspan="1">(77.0&#x000a0;&#x000b1;&#x000a0;1.4)</td><td align="left" rowspan="1" colspan="1">(74.3&#x000a0;&#x000b1;&#x000a0;0.8)</td><td align="left" rowspan="1" colspan="1">(77.7&#x000a0;&#x000b1;&#x000a0;1.0)</td><td align="left" rowspan="1" colspan="1">(76.3&#x000a0;&#x000b1;&#x000a0;1.2)</td><td align="left" rowspan="1" colspan="1">(77.2&#x000a0;&#x000b1;&#x000a0;1.6)</td></tr><tr><td align="left" rowspan="3" colspan="1">Heart rate (b.p.m.)</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">130</td><td align="left" rowspan="1" colspan="1">53</td><td align="left" rowspan="1" colspan="1">138</td><td align="left" rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">66</td><td align="left" rowspan="1" colspan="1">46</td></tr><tr><td align="left" rowspan="1" colspan="1">Changes at week 12</td><td align="left" rowspan="1" colspan="1">0.19&#x000a0;&#x000b1;&#x000a0;0.51</td><td align="left" rowspan="1" colspan="1">&#x02212;2.40&#x000a0;&#x000b1;&#x000a0;1.06<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">0.17&#x000a0;&#x000b1;&#x000a0;0.55</td><td align="left" rowspan="1" colspan="1">&#x02212;5.78&#x000a0;&#x000b1;&#x000a0;0.95<xref ref-type="fn" rid="jdi12726-note-0003">**</xref>
</td><td align="left" rowspan="1" colspan="1">0.25&#x000a0;&#x000b1;&#x000a0;0.67</td><td align="left" rowspan="1" colspan="1">&#x02212;3.92&#x000a0;&#x000b1;&#x000a0;1.23<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">(60.71&#x000a0;&#x000b1;&#x000a0;0.54)</td><td align="left" rowspan="1" colspan="1">(77.34&#x000a0;&#x000b1;&#x000a0;0.89)</td><td align="left" rowspan="1" colspan="1">(60.92&#x000a0;&#x000b1;&#x000a0;0.48)</td><td align="left" rowspan="1" colspan="1">(77.32&#x000a0;&#x000b1;&#x000a0;1.14)</td><td align="left" rowspan="1" colspan="1">(61.29&#x000a0;&#x000b1;&#x000a0;0.69)</td><td align="left" rowspan="1" colspan="1">(78.20&#x000a0;&#x000b1;&#x000a0;1.19)</td></tr></tbody></table><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="9" valign="top" rowspan="1">Placebo</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="2" valign="top" rowspan="1">Variable (heart rate at baseline)</th><th align="left" valign="top" rowspan="1" colspan="1">&#x0003c;55 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;55 to &#x0003c;60 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;60 to &#x0003c;65 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;65 to &#x0003c;70 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;70 to &#x0003c;75 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;75 to &#x0003c;80 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;80 b.p.m.</th></tr></thead><tbody><tr><td align="left" rowspan="3" colspan="1">Heart rate (b.p.m.)</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">28</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">38</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">14</td></tr><tr><td align="left" rowspan="1" colspan="1">Changes at week 12</td><td align="left" rowspan="1" colspan="1">1.47&#x000a0;&#x000b1;&#x000a0;0.76</td><td align="left" rowspan="1" colspan="1">1.70&#x000a0;&#x000b1;&#x000a0;0.82</td><td align="left" rowspan="1" colspan="1">&#x02212;0.54&#x000a0;&#x000b1;&#x000a0;0.81</td><td align="left" rowspan="1" colspan="1">&#x02212;0.92&#x000a0;&#x000b1;&#x000a0;1.27</td><td align="left" rowspan="1" colspan="1">&#x02212;1.33&#x000a0;&#x000b1;&#x000a0;1.94</td><td align="left" rowspan="1" colspan="1">&#x02212;2.55&#x000a0;&#x000b1;&#x000a0;1.34</td><td align="left" rowspan="1" colspan="1">&#x02212;3.91&#x000a0;&#x000b1;&#x000a0;2.10</td></tr><tr><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">(51.59&#x000a0;&#x000b1;&#x000a0;0.54)</td><td align="left" rowspan="1" colspan="1">(57.48&#x000a0;&#x000b1;&#x000a0;0.29)</td><td align="left" rowspan="1" colspan="1">(62.34&#x000a0;&#x000b1;&#x000a0;0.22)</td><td align="left" rowspan="1" colspan="1">(67.50&#x000a0;&#x000b1;&#x000a0;0.24)</td><td align="left" rowspan="1" colspan="1">(72.38&#x000a0;&#x000b1;&#x000a0;0.33)</td><td align="left" rowspan="1" colspan="1">(76.90&#x000a0;&#x000b1;&#x000a0;0.35)</td><td align="left" rowspan="1" colspan="1">(85.66&#x000a0;&#x000b1;&#x000a0;1.76)</td></tr></tbody></table><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="9" valign="top" rowspan="1">2.5 mg luseogliflozin</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="2" valign="top" rowspan="1">Variable (heart rate at baseline)</th><th align="left" valign="top" rowspan="1" colspan="1">&#x0003c;55 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;55 to &#x0003c;60 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;60 to &#x0003c;65 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;65 to &#x0003c;70 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;70 to &#x0003c;75 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;75 to &#x0003c;80 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;80 b.p.m.</th></tr></thead><tbody><tr><td align="left" rowspan="4" colspan="1">Heart rate (b.p.m.)</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">20</td><td align="left" rowspan="1" colspan="1">34</td><td align="left" rowspan="1" colspan="1">43</td><td align="left" rowspan="1" colspan="1">41</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">13</td></tr><tr><td align="left" rowspan="1" colspan="1">Changes at week 12</td><td align="left" rowspan="1" colspan="1">1.76&#x000a0;&#x000b1;&#x000a0;1.16</td><td align="left" rowspan="1" colspan="1">0.78&#x000a0;&#x000b1;&#x000a0;1.06</td><td align="left" rowspan="1" colspan="1">&#x02212;0.78&#x000a0;&#x000b1;&#x000a0;0.80</td><td align="left" rowspan="1" colspan="1">&#x02212;0.13&#x000a0;&#x000b1;&#x000a0;1.26</td><td align="left" rowspan="1" colspan="1">&#x02212;4.39&#x000a0;&#x000b1;&#x000a0;1.17<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;5.91&#x000a0;&#x000b1;&#x000a0;1.61<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02212;8.40&#x000a0;&#x000b1;&#x000a0;2.58<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">(51.24&#x000a0;&#x000b1;&#x000a0;0.60)</td><td align="left" rowspan="1" colspan="1">(57.57&#x000a0;&#x000b1;&#x000a0;0.24)</td><td align="left" rowspan="1" colspan="1">(62.12&#x000a0;&#x000b1;&#x000a0;0.25)</td><td align="left" rowspan="1" colspan="1">(67.16&#x000a0;&#x000b1;&#x000a0;0.19)</td><td align="left" rowspan="1" colspan="1">(71.75&#x000a0;&#x000b1;&#x000a0;0.27)</td><td align="left" rowspan="1" colspan="1">(76.82&#x000a0;&#x000b1;&#x000a0;0.33)</td><td align="left" rowspan="1" colspan="1">(89.12&#x000a0;&#x000b1;&#x000a0;2.85)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>P</italic> value (vs placebo, ANOVA)</td><td align="left" rowspan="1" colspan="1">0.885</td><td align="left" rowspan="1" colspan="1">0.560</td><td align="left" rowspan="1" colspan="1">0.829</td><td align="left" rowspan="1" colspan="1">0.585</td><td align="left" rowspan="1" colspan="1">0.142</td><td align="left" rowspan="1" colspan="1">0.120</td><td align="left" rowspan="1" colspan="1">0.278</td></tr></tbody></table><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="9" valign="top" rowspan="1">5.0&#x000a0;mg luseogliflozin</th></tr><tr style="border-bottom:solid 1px #000000"><th align="left" colspan="2" valign="top" rowspan="1">Variable (heart rate at baseline)</th><th align="left" valign="top" rowspan="1" colspan="1">&#x0003c;55 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;55 to &#x0003c;60 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;60 to &#x0003c;65 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;65 to &#x0003c;70 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;70 to &#x0003c;75 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;75 to &#x0003c;80 b.p.m.</th><th align="left" valign="top" rowspan="1" colspan="1">&#x02265;80 b.p.m.</th></tr></thead><tbody><tr><td align="left" rowspan="4" colspan="1">Heart rate (b.p.m.)</td><td align="left" rowspan="1" colspan="1">
<italic>n</italic>
</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">22</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">19</td><td align="left" rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">Changes at week 12</td><td align="left" rowspan="1" colspan="1">3.23&#x000a0;&#x000b1;&#x000a0;0.99<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td><td align="left" rowspan="1" colspan="1">0.19&#x000a0;&#x000b1;&#x000a0;1.34</td><td align="left" rowspan="1" colspan="1">1.53&#x000a0;&#x000b1;&#x000a0;0.97</td><td align="left" rowspan="1" colspan="1">&#x02212;2.27&#x000a0;&#x000b1;&#x000a0;1.39</td><td align="left" rowspan="1" colspan="1">&#x02212;2.07&#x000a0;&#x000b1;&#x000a0;2.12</td><td align="left" rowspan="1" colspan="1">&#x02212;3.42&#x000a0;&#x000b1;&#x000a0;1.81</td><td align="left" rowspan="1" colspan="1">&#x02212;7.45&#x000a0;&#x000b1;&#x000a0;2.62<xref ref-type="fn" rid="jdi12726-note-0003">*</xref>
</td></tr><tr><td align="left" rowspan="1" colspan="1">At baseline</td><td align="left" rowspan="1" colspan="1">(50.56&#x000a0;&#x000b1;&#x000a0;1.43)</td><td align="left" rowspan="1" colspan="1">(57.69&#x000a0;&#x000b1;&#x000a0;0.32)</td><td align="left" rowspan="1" colspan="1">(62.04&#x000a0;&#x000b1;&#x000a0;0.31)</td><td align="left" rowspan="1" colspan="1">(67.79&#x000a0;&#x000b1;&#x000a0;0.32)</td><td align="left" rowspan="1" colspan="1">(71.77&#x000a0;&#x000b1;&#x000a0;0.36)</td><td align="left" rowspan="1" colspan="1">(77.46&#x000a0;&#x000b1;&#x000a0;0.37)</td><td align="left" rowspan="1" colspan="1">(88.84&#x000a0;&#x000b1;&#x000a0;2.93)</td></tr><tr><td align="left" rowspan="1" colspan="1">
<italic>P&#x02010;</italic>value (vs placebo, ANOVA)</td><td align="left" rowspan="1" colspan="1">0.281</td><td align="left" rowspan="1" colspan="1">0.311</td><td align="left" rowspan="1" colspan="1">0.151</td><td align="left" rowspan="1" colspan="1">0.534</td><td align="left" rowspan="1" colspan="1">0.616</td><td align="left" rowspan="1" colspan="1">0.660</td><td align="left" rowspan="1" colspan="1">0.434</td></tr></tbody></table><table-wrap-foot><fn id="jdi12726-note-0001"><p>ALT, alanine aminotransferase; ANOVA, analysis of variance; AST, aspartate aminotransferase; BMI, body mass index; b.p.m., beats per minute; BUN, blood urea nitrogen; DBP, diastolic blood pressure; FPG, fasting plasma glucose; HbA1c, glycosylated hemoglobin; HDL&#x02010;C, high&#x02010;density lipoprotein cholesterol; LDL&#x02010;C, low&#x02010;density lipoprotein cholesterol; SBP, systolic blood pressure.</p></fn><fn id="jdi12726-note-0002"><p>Mean&#x000a0;&#x000b1;&#x000a0;SE.</p></fn><fn id="jdi12726-note-0003"><p>*<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05, versus baseline, paired t&#x02010;test. **<italic>P</italic>&#x000a0;=&#x000a0;0.016, versus placebo, ANOVA for heart rate only.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>The incidence of adverse events among patients with HR &#x02265;70&#x000a0;b.p.m. and HR &#x0003c;70&#x000a0;b.p.m. at baseline was 40.4% and 42.3%, respectively, in the luseogliflozin 2.5&#x000a0;mg group, and 50.0% and 34.8%, respectively, in the luseogliflozin 5.0&#x000a0;mg group. Although the incidence of adverse events was higher in the 5.0&#x000a0;mg group with higher baseline HR, there were no remarkable adverse events in the higher dose group. Throughout the studies, luseogliflozin was well tolerated. It is suggested that luseogliflozin can effectively decrease the HR in patients with higher baseline HR. Some patients with type&#x000a0;2 diabetes mellitus have elevated central sympathetic activity, which is exacerbated by a malfunction of the negative feedback mechanism as a result of decreased sensitivity of baroreceptor reflexes<xref rid="jdi12726-bib-0005" ref-type="ref">5</xref>, <xref rid="jdi12726-bib-0006" ref-type="ref">6</xref>. This results in elevation of peripheral sympathetic activity in the heart, leading to an increase in resting HR. These results suggest that luseogliflozin could calm elevated central sympathetic activity, while having no such effect in patients with normal central sympathetic activity.</p><sec id="jdi12726-sec-0002"><title>Disclosure</title><p>YS received consulting and/or speaker's fees from Eli Lilly Japan K.K., Sanofi K.K., Novo Nordisk Pharma Inc., Glaxo&#x02010;Smith&#x02010;Kline, Taisho Pharmaceutical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Astellas Pharma Inc., BD, Nippon Boehringer Ingelheim Co., Ltd., Johnson &#x00026; Johnson and Takeda Pharmaceutical Company Limited. YS also received clinical commissioned/joint research grants from Nippon Boehringer Ingelheim Co., Ltd., Eli Lilly and Company, Taisho Toyama Pharmaceutical Co., Ltd., MSD K.K., Ono Pharmaceutical Co., Ltd., Novo Nordisk Pharma Ltd., and ARKRAY, Inc. MS received joint research grants from Taisho Toyama Pharmaceutical Co., Ltd. HI, HO and SC are employees of Taisho Pharmaceutical Co., Ltd.</p></sec></body><back><ref-list content-type="cited-references" id="jdi12726-bibl-0001"><title>References</title><ref id="jdi12726-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jdi12726-cit-0001">
<string-name>
<surname>Hillis</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>Hata</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Woodward</surname>
<given-names>M</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Resting heart rate and the risk of microvascular complications in patients with type 2 diabetes mellitus</article-title>. <source>J Am Heart Assoc</source>
<year>2012</year>; <volume>1</volume>: <fpage>e002832</fpage>.<pub-id pub-id-type="pmid">23316296</pub-id></mixed-citation></ref><ref id="jdi12726-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jdi12726-cit-0002">
<string-name>
<surname>Seino</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Sasaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Fukatsu</surname>
<given-names>A</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Dose&#x02010;finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12&#x02010;week, randomized, double&#x02010;blind, placebo&#x02010;controlled, phase II study</article-title>. <source>Curr Med Res Opin</source>
<year>2014</year>; <volume>30</volume>: <fpage>1231</fpage>&#x02013;<lpage>1244</lpage>.<pub-id pub-id-type="pmid">24673496</pub-id></mixed-citation></ref><ref id="jdi12726-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jdi12726-cit-0003">
<string-name>
<surname>Seino</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Sasaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Fukatsu</surname>
<given-names>A</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Efficacy and safety of luseogliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a 12&#x02010;week, randomized, placebo&#x02010;controlled, phase II study</article-title>. <source>Curr Med Res Opin</source>
<year>2014</year>; <volume>30</volume>: <fpage>1219</fpage>&#x02013;<lpage>1230</lpage>.<pub-id pub-id-type="pmid">24597840</pub-id></mixed-citation></ref><ref id="jdi12726-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jdi12726-cit-0004">
<string-name>
<surname>Seino</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Sasaki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Fukatsu</surname>
<given-names>A</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double&#x02010;blind, placebo&#x02010;controlled, phase 3 study</article-title>. <source>Curr Med Res Opin</source>
<year>2014</year>; <volume>30</volume>: <fpage>1245</fpage>&#x02013;<lpage>1255</lpage>.<pub-id pub-id-type="pmid">24708292</pub-id></mixed-citation></ref><ref id="jdi12726-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jdi12726-cit-0005">
<string-name>
<surname>Huggett</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Scott</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Gilbey</surname>
<given-names>SG</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Impact of type 2 diabetes mellitus on sympathetic neural mechanisms in hypertension</article-title>. <source>Circulation</source>
<year>2003</year>; <volume>108</volume>: <fpage>3097</fpage>&#x02013;<lpage>4101</lpage>.<pub-id pub-id-type="pmid">14676139</pub-id></mixed-citation></ref><ref id="jdi12726-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jdi12726-cit-0006">
<string-name>
<surname>Ruiz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Monbaron</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Parati</surname>
<given-names>G</given-names>
</string-name>, <italic>et&#x000a0;al</italic>
<article-title>Diabetic neuropathy is a more important determinant of baroreflex sensitivity than carotid elasticity in type 2 diabetes</article-title>. <source>Hypertension</source>
<year>2005</year>; <volume>46</volume>: <fpage>162</fpage>&#x02013;<lpage>167</lpage>.<pub-id pub-id-type="pmid">15928031</pub-id></mixed-citation></ref></ref-list></back></article>